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Objectives. The aim of this study was to evaluate the diagnostic performance of BD GeneOhm VanR Assay, a rapid PCR test
that detects the presence of vanA and/or vanB genes and the performance of BDGeneOhm MRSA Assay which detects the
staphylococcal cassette chromosomemec (SCCmec cassette) carrying the mecA gene and Staphylococcus aureus speciﬁc sequence
located within the orfX gene. Methods. 300 duplicate rectal swabs collected consecutively were analyzed for the presence of VRE
by culture and BD PCR. 2267 duplicate swabs were collected (728 nasal and 1539 groin swabs) and analyzed for the presence
of MRSA by culture method and BD PCR. Results. Compared to culture, the BD GeneOhm VanR Assay showed a sensitivity,
speciﬁcity, positive predictive value (PPV) and negative predictive value (NPV) of 100%, 91.1%, 23.5%, and 100%, respectively.
The BD GeneOhm MRSA Assay revealed sensitivity, speciﬁcity, PPV, and NPV of 97.2%, 99.4%, 89.7%, and 99.9%, respectively,
fornasalswabs.Forgroinswabs,itwas100%,98.7%,61.5%and100%,respectively.Conclusion.TheBDGeneOhmvanRAssayisa
good screening test for rapid exclusion of VRE carriers in hospitals. The BD GeneOhm MRSA Assay represents a reliable screening
test. The true strength of the BD GeneOhm Assay for MRSA and VRE is its exceptionally high NPV making the test an ideal tool
for rapid exclusion of MRSA and VRE carriers in hospitals. As a consequence, this would dramatically shorten the patient isolation
time.
1.Introduction
Methicillin-resistant staphylococcus aureus (MRSA) and van-
comycin-resistant enterococcus (VRE) are multidrug resis-
tant organisms and are particularly frequent causes of hos-
pital-acquired infections that are often diﬃcult and expen-
sive to treat [1].
Methicillin resistance in S. aureus is primarily mediated
by the mecA gene, which codes for the modiﬁed penicillin-
binding protein 2a (PBP 2a) [1]. Several studies on S. aureus
suggest that MRSA infection usually follows prior carriage
rather than occurring from direct transmission during inva-
sive procedures by staﬀ or from intensive care unit (ICU)
environment [2–5], meaning that MRSA infection is pre-
cededbycolonizationwithanMRSAstrainthatisgenetically
indistinguishablefromthediseasecausingisolationinatleast
56% of patients. These data support the view that prevention
of colonization of ICU patients with MRSA could reduce the
frequency of MRSA infections and can assist in the design of
eﬀective prevention strategies against MRSA infection [6].
Enterococciinhabitthegastrointestinaltractandarecon-
sidered normal ﬂora. Their emergence as important patho-
gens in the past two decades is largely due to their resistance
to many commonly used antibiotics [7]. Most enterococcal2 International Journal of Microbiology
infections have been attributed to endogenous sources
(normal ﬂora of individual patient), yet transmission occurs
by contaminated hands of personnel, contaminated patient-
care equipment, and/or environmental surfaces. Treatment
of some enterococcalinfection has become a signiﬁcant chal-
lenge, especially with the emergence of strains resistant to
vancomycin [1]. A few genes are responsible for vancomycin
resistance (intrinsic or acquired). The vanA and vanB
genes are those predominantly encountered in vancomycin-
resistant enterococci (VRE). They are transferable and
can spread from organism to organism and are the only
ones that are clinically relevant. In contrast, vanC genes
are not transferable, have been associated less commonly
with serious infections, and have not been associated with
outbreaks [8]. Early screening of patients for VRE carriage
to identify those patients that require isolation can be
part of an eﬀective infection control program for VRE
[9, 10].
In most laboratories conventional culture and identiﬁca-
tion method are considered the gold standard in screening
for VRE and MRSA colonization. Since results need a turn-
around time (TAT) of 2–4 days which is not compatible to
being proactive in terms of infection prevention and control,
a test that has a faster TAT and is comparable to culture in
eﬃciency and cost-eﬀectiveness is needed [11–13]. Recently
several rapid diagnostic tests have been introduced that
would be very beneﬁcial in decreasing the time to detection
(several hours), therefore reducing the risk of nosocomial
transmission and infections especially in high risk patients
[13–18].
The BD GeneOhm MRSA Assay is a multiplex quan-
titative real-time PCR assay and is a US Food and Drug
administration (FDA) cleared qualitative in vitro test for di-
rect detection of nasal colonization by MRSA [1]. Its use on
specimens from alternative sites has not been FDA approved.
The use of this assay in clinical setting requires conﬁrmation
especially on swabs from sites other than the nose [19]. It
detects the SCCmec cassette (carrying the mecA gene) and
an S. aureus speciﬁc sequence located within the orfX gene,
allowing discrimination between MRSA and methicillin-
resistant coagulase-negative staphylococci [1].
The BD GeneOhm VanR Assay is a CE-mark in vitro test
for the rapid detection of vancomycin-resistant (vanA and
vanB) genes directly from perianal and/or rectal swabs. The
BD GeneOhm VanR Assay can be used as an aid to identify,
prevent, and control vancomycin-resistant colonization in
healthcare settings [13]. It is not intended to diagnose
VRE infection nor to guide or monitor treatment for VRE.
Concomitant cultures are necessary to recover organisms for
conﬁrmatory identiﬁcation [20].
King Fahad Specialist Hospital Dammam (600 bed total
capacity) has oncology centre and is establishing bone mar-
row and solid organ transplant programs and does have
guidelines for hospital wide screening of new hospital
admission for MRSA and VRE. The development of reliable
and rapid method for the identiﬁcation of patients colonized
with MRSA and VRE is central to the containment of this
agent within the hospital environment. To this end, we
investigated the performance of the BD GeneOhm Assays
as an alternative to culture which requires 2-3 days before
implementing it as a rapid screening method in the hospital.
2.MaterialsandMethods
Patients and specimens were screened for MRSA and VRE.
In the present study, 2267 duplicate swabs were collected
(728 nasal and 1539 groin swabs) between January 2008 and
June 2009 from all new hospital admissions. In addition, 300
duplicate rectal swabs were collected consecutively between
January 2009 and June 2009 from the all patients admitted to
the intensive care unit. Nasal and groin swabs were analyzed
for the presence of MRSA by conventional culture method
and BD GeneOhm MRSA Assay. Rectal swabs were analyzed
for the presence of VRE by culture and BD GeneOhm
VanR Assay. The duplicate nasal, groin, and rectal swabs
from each patient were obtained by nursing staﬀ using BBL
CultureSwab Liquid Stuart single swab (Becton Dickinson).
For each assay, the two swabs were randomly separated in
the laboratory. One swab was used for direct and enrichment
brothculture,whilePCRwasperformedwiththeotherswab.
If processing of the swabs was not possible on the same
day, swabs were stored overnight at 4◦C. The BD GeneOhm
MRSAAssayisFDAapprovedforthedirectdetectionofnasal
colonization by MRSA only. However, we used it for both
nasal and groin swabs.
2.1. Conventional Culture Identiﬁcation and Susceptibility
Testing for MRSA. Collected swabs were inoculated onto
blood agar plate (BA), mannitol salt agar (MSA), Mueller
hinton with 4% NaCl and oxacillin (MOX) agar, Columbia
polymyxin nalidixic acid and bacitracin agar (PNBA) and
theninoculatedintosaltbroth.Plateswereincubatedat37◦C
for 24h. Suspected colonies were identiﬁed by conventional
laboratory methods, including Gram stain, Catalase test, and
coagulase production by the tube method [21]. Coagulase
positive strains were inoculated on oxacillin screen plate and
tested for susceptibility to cefoxitin disc and oxacillin E-test
strips. Strains of Staphylococcus aureus isolated directly from
the agar and/or broth cultures that give a zone of ≤21mm
w i t hc e f o x i t i no ra nM I Co f≥4 with the oxacillin E-test
werereportedasMRSAaccordingtoClinicalandLaboratory
Standards Institute (CLSI) guidelines [22].
2.2. BD GeneOhm MRSA Assay. The BD GeneOhm MRSA
Assay was performed as recommended by the manufacturer.
The tip of the swab was broken oﬀ into an MRSA sample
buﬀertubecontainingaTris-EDTAsamplepreparationbuﬀ-
er, provided by the manufacturer. After the sample buﬀer
tube was vortexed for 1min, 50µL of the solution was
transferred into a lysis tube. The lysis tube was vortexed
for 5 minutes at high speed and received a quick spin in
the centrifuge to bring the contents to the bottom of the
tube before incubation at 95◦Ci nad r yh e a t i n gb l o c kf o r
2 minutes. The sample was kept at 2 to 8◦C until PCR
testing.ThePCRprocessingwasperformedasrecommended
by the manufacturer using the Smart Cycler II instrument
(Cepheid, Sunnyvale, Calif, USA). Positive and negative
controls were included in each run. The assay results wereInternational Journal of Microbiology 3
interpreted as follows: “NEG,” no MRSA DNA was detected;
“POS,” MRSA DNA was detected; “unresolved,” the IC was
inhibited or there was reagent failure; “not determined,”
there was an I-CORE module malfunction.
2.2.1. Quality Control. In addition to the previously men-
tioned PCR control for each run, a reference MRSA strain
(ATCC 4300) and a reference MSSA strain (ATCC 29213)
were included in each assay and on day of use with MOX
agar.
2.3. Conventional Culture Identiﬁcation and Susceptibility
Testing for VRE . Rectal swabs for culture were ﬁrst inocu-
lated onto Columbia PNBA and then into salt broth. Plates
were incubated at 35◦C in ambient air and examined for
growth at 24 and 48 hours. Broth cultures were incubated at
35◦C.Anysuspectedcolonieswereidentiﬁedbyconventional
laboratory methods, including Gram stain, Catalase test, bile
esculinagar(BEA)test,andBVS(Vancomycinscreeningagar
that incorporates the use of 6 ug/mL of vancomycin in brain-
heart infusion (BHI) agar) [21]. Black colonies (esculin-
positive) were then subcultured onto a blood agar plate for
purity. Following 24 hours of incubation, a deﬁnite spot
of growth or greater than one colony present at the site of
inoculation on the BVS agar indicates that the Enterococci
may be a VRE [23]. Identiﬁcation (E. faecalis/E. faecium)
was conﬁrmed by performing GP on the vitek 2 system
(bioMerieux; GP colorimetric identiﬁcation card). Suscepti-
bility testing was performed on conﬁrmed enterococcal iso-
lates using vancomycin (0.016 to 256µg/mL) and teicoplanin
(0.016 to 256µg/mL) E-test strips. The determination of
the MICs and the interpretation of vancomycin resistance
(MIC ≥ 32µg/mL) were done according to Clinical and
Laboratory Standards Institute (CLSI) guidelines [21]. For
the interpretation of the teicoplanin results, combination of
the intermediate and resistant MICs was done as previously
publishedfortheassignmentofisolatesashavingvanA(MIC
≥ 16µg/mL) or vanB( M I C< 16µg/mL) [13].
2.3.1. BD GeneOhm VanR Assay. For BD GeneOhm VanR
Assay, the assay was performed by following the manufac-
turer protocol and as described elsewhere [13]. The tip of
the swab was broken oﬀ into a VanR sample buﬀer tube
containing a Tris-EDTA sample preparation buﬀer, provided
by the manufacturer. After the sample buﬀer tube was
vortexed for 1min, 50µL of the solution was transferred into
al y s i st u b e .T h el y s i st u b ew a sv o r t e x e df o r5m i n u t e sa th i g h
speed and received a quick spin in the centrifuge to bring
the contents to the bottom of the tube before incubation
at 95◦C in a dry heating block for 2 minutes. The sample
was kept at 2 to 8◦C until PCR testing. The PCR processing
was performed as recommended by the manufacturer using
the Smart Cycler II instrument (Cepheid, Sunnyvale, Calif,
USA). Positive and negative controls were included in each
run. The assay results were interpreted as follows: “negative,”
no vanA or vanB DNA was detected; “positive,” vanA and
vanB DNA was detected; “Presumptive POS,” vanB DNA was
detected;“POS,”vanAwasdetected;“unresolved,”theICwas
inhibited or there was reagent failure; “invalid assay run,” the
PCR control (positive or negative) failed; “not determined,”
there was an I-CORE module malfunction.
2.3.2. Quality Control. In addition to the previously men-
tioned PCR control for each run, a reference VRE strain
(E. faecalis ATCC 51299) and a reference E. faecalis Van-
comycin susceptible strain (ATCC 29212) were included in
each assay and on day of use with the BVS agar.
2.4. Resolution of Discordant Results. If any of the BD
GeneOhmforMRSAandVREwasunresolved,thatgenerally
would indicate some amount of PCR inhibition. The assay
was repeated once using the frozen lysate as recommended
in the kit directions. Unresolved specimens after repetition
were excluded from ﬁnal analysis. For the only sample in
which the BD GeneOhm was negative for MRSA but the
culture was MRSA positive, the original frozen lysate and the
corresponding isolate were tested again by the BD GeneOhm
MRSA Assay. BD GeneOhm positive samples, which were
culture negative, were examined again by inoculating 300µL
of cell suspension from the sample buﬀer including the swab
intoasaltenrichmentbroth.Thiswasfollowedbyincubation
for 18–24hours in air at 35◦C and the subculture onto ap-
propriate culture media.
2.5. Statistical Analysis. Descriptive statistical performance
characteristics were calculated for the BD GeneOhm MRSA
and VanR Assays relative to gold standard direct culture and
broth enrichment culture results. The sensitivity, speciﬁcity,
positivepredictivevalue(PPV),andnegativepredictivevalue
(NPV) were calculated according to standard formulas. The
commercial statistical software package used was SPSS 11.0
(SPSS, Inc., Chicago, ILL, USA) and was used for statistical
evaluation of results.
3. Results
For detection of MRSA, a total of 2283 swabs were collected
and tested as described above. Thirty-two (32) specimens
were inhibited in the PCR assay with an initial unresolved
rate being 1.4% of which 16 (0.7%) were resolved following
freeze thaw of the lysate and repeat of PCR testing. The
remaining 16 unresolved samples were excluded in the data
analysis resulting in 2267 total swabs. The 2267 swabs (728
nasal and 1539 groin swabs) were tested. Of the 728 nasal
swabs, 35 swabs (4.8%) revealed MRSA by culture. The 1539
groin swabs revealed MRSA in 32 swabs (2.1%) by culture.
In the BD GeneOhm MRSA Assay, 39 nasal swabs (5.4%)
were positive and 52 groin swabs (3.4%) were positive.
Tables 1 and 2 show the distribution of positive and negative
samples by both methods. One MRSA nasal isolate was
detected by culture and was negative by PCR (false negative).
Four nasal (0.5%) and 20 groin swabs (1.3%) were positive
with the BD GeneOhm MRSA Assay and did not reveal
MRSA in culture (false positive).
The BD GeneOhm MRSA Assay showed sensitivity (the
proportion of actual MRSA positives which are correctly
identiﬁed as such), speciﬁcity (the proportion of actual
MRSA negatives which are correctly identiﬁed as such),4 International Journal of Microbiology
Table 1: Comparison of BD GeneOhm MRSA and culture in the







P O S 3 543 9
Negative 1 688 689
Total 36 692 728
Table 2: Comparison of BD GeneOhm MRSA Assay and culture in







P O S 3 22 05 2
Negative 0 1487 1487
Total 32 1507 1539
PPV (the proportion of positive MRSA with PCR who are
correctly diagnosed), and NPV (the proportion of negative
MRSA with PCR who are correctly diagnosed) of 97.2%,
99.4%, 89.7% and 99.9%, respectively for direct detection
from nasal swabs. For direct detection from groin samples,
it was 100%, 98.7%, 61.5%, and 100%, respectively. Table 3
shows sensitivity, speciﬁcity, PPV, and NPV of the BD
GeneOhm MRSA Assay using nasal and groin swabs.
The 300 rectal swabs revealed VRE in 8 samples by
culture, and 292 samples were negative. The 8 strains were
E. faecium and all of them were resistant to vancomycin
and sensitive to teicoplanin (phenotype B). The overall prev-
alence of VRE by culture was 2.7%. The BD GeneOhm
VanR Assay detected vanB gene in 34 samples (11.3%).
vanA gene was not detected in any sample. Twenty-six rectal
swabs (8.7%) revealed vanB gene by BD GeneOhm VanR
Assay but did not grow enterococci in culture (false +ve).
The distribution of positive and negative samples by both
methods is shown in Table 4. Compared to conventional
culture, the BD GeneOhm VanR Assay showed a sensitivity
(the proportion of actual VRE positives which are correctly
identiﬁed as such), speciﬁcity (the proportion of actual VRE
negatives which are correctly identiﬁed as such), PPV (the
proportion of positive VRE with PCR who are correctly
diagnosed), and NPV (the proportion of negative VRE with
PCR who are correctly diagnosed) of 100%, 91.1%, 23.5%,
and 100%, respectively.
4. Discussion
Active surveillance culture from patients for carriage of
MRSA and VRE facilitates early contact isolation, thus pre-
ventingspreadinhospitalandreducingcosts[1].KingFahad
specialist hospital-Dammam has guidelines for hospital wide
screening of new hospital admissions for MRSA and VRE.
The time to result with conventional culture is 2–4 days. A
rapid, accurate tool that identify carriers is a key component
of any infection control program to reduce transmission.
In this study, we evaluated the detection performance of
Table 3: Sensitivity, speciﬁcity, positive predictive value (PPV), and
negative predictive value (NPV) of the BD GeneOhm Assay MRSA
real-time PCR using nasal and groin swabs.
Value % (95% CI)
Type of sample
Nasal swabs (728) Groin swabs
(1539)
Sensitivity1 97.2% (0.83–0.99) 100% (0.86–1)
Speciﬁcity2 99.4% (0.98–0.99) 98.7% (0.97–0.99)
PPV3 89.7% (0.74–0.96) 61.5% (0.47–0.74)
NPV4 99.9% (0.99–0.99) 100% (0.99–1)
1The proportion of actual positives by PCR which are correctly identiﬁed as
such.
2The proportion of actual negatives by PCR which are correctly identiﬁed as
such.
3The proportion of positive test results with PCR who are correctly
diagnosed.
4The proportion of negative test results with PCR who are correctly
diagnosed.
Table 4: Comparison of BD GeneOhm VanR Assay and culture in






POS 8 26 34
Negative 0 266 266
Total 8 292 300
(Sensitivity: 100%; speciﬁcity: 91.1%; positive predictive value (PPV):
23.5%; negative predictive value (NPV): 100%).
the BD GeneOhm VanR Assay, a rapid real-time PCR test
that detects the presence of vanA and/or vanB, and the BD
GeneOhm MRSA Assay which detects SCCmec cassette and
S. aureus speciﬁc sequence located within the orfX gene,
allowing discrimination between MRSA and methicillin-
resistantcoagulase-negativestaphylococci.BDGeneOhmfor
both MRSA and VanR Assays oﬀer rapid identiﬁcation of
MRSAandVREcolonizedpatientsinaslittleas2hours[13].
The BD GeneOhm MRSA Assay was compared to
culture. The BD GeneOhm MRSA Assay showed a high
speciﬁcity with nasal and groin samples (99.4% and 98.7%,
resp.).Thesensitivitywasalsohigherinourgroupofpatients
(97.2% and 100%) compared with that of Lucke et al.
[24] who reported a lower sensitivity (84.3%). This may
be attributed to the type of specimens that was collected
from diﬀerent clinical conditions and from diﬀerent sites.
Screening for MRSA from groin swabs is considered a
modiﬁed FDA-cleared test. Therefore, we examined 1539
specimens to come across a minimum of 50 specimens that
contain the target analyte and a minimum of 100 specimens
that lack the target analyte [25].
There is a general consensus for multiple body site
screening to achieve optimal detection of MRSA. Consider-
ing pooling of the specimen may reduce the cost of the assay;
Bishop et al. [26] showed sensitivities and speciﬁcities for
pooled nose-groin specimen comparable to those processed
separately with the BD GeneOhm MRSA Assay.International Journal of Microbiology 5
In our group, the PPV was 89.7% with the nasal swabs
and it was diminished to 61.5% with the groin swabs.
Recent studies [19, 27] reported PPVs ranging from 63%
in a community setting to 94% in hospital setting. The
high NPV in this study (nasal 99.9% and groin 100%) and
those reported by others [28, 29] suggest that this assay
provides a rapid method for the identiﬁcation of persons
who are not colonized with MRSA and in that context is
likely to be useful for epidemiologic or surveillance activity
in a hospital environment. The 24 swabs that detected MRSA
by the BD GeneOhm MRSA Assay and were not recovered
in culture may belong to patients receiving antibiotics [30].
The BD GeneOhm MRSA Assay result may sometimes be
unresolved and may require retesting that can lead to a delay
in obtaining ﬁnal results. This problem was met with 32
of our samples and half of them were resolved after repeat
testing of the corresponding frozen lysates for specimen and
controls. The frozen-thaw cycles have been shown to reduce
PCR inhibitors substances in the specimen lysate [29, 30].
One of our MRSA isolates from the nose was not detected by
the BD GeneOhm MRSA Assay giving false negative result.
This was also reported in a study done by Bartels et al. in
Copenhagen [31], as more than one-third of their MRSA
isolates were not detected. They recommended that the BD
GeneOhm MRSA Assay be evaluated against the local MRSA
diversitybeforebeingestablishedasastandardassay,anddue
to the constant evolution of SCCmec cassettes, a continuous
global surveillance is advisable in order to update the assay
[31]. In the present study, the BD GeneOhm MRSA Assay
had a high sensitivity (97% and 100% for nasal and groin
swabs, resp.) and thus, can be regarded as reliable in our
hospital.
In conclusion, the BD GeneOhm MRSA Assay represents
a reliable screening test when applied to nasal and groin
specimens. The true strength of this assay is its exceptionally
high NPV (98.9%) making the test an ideal tool for rapid
exclusion of MRSA carriers in hospitals. As a consequence,
this would dramatically shorten the patient isolation time.
In this study, the BD GeneOhm VanR Assay detected
vanB gene in 34 samples, eight of them revealed E. faecium
that were phenotypically vanB. The BD GeneOhm VanR
Assay has speciﬁcity 91.1% with a positive predictive value
of 23.5%. This poor positive predictive value with the assay
was also reported by other workers [32]. This was explained
bythehighprevalenceofvanBgenesnotassociatedwithVRE
from human rectal swabs. Graham et al. [33] demonstrated
high rates of nonenterococcal vanB carriage in hemodialysis
patients (45%), community adults (63%), and children
(27%). This is attributed to the presence of gut anaerobes
carrying the vanB containing transposons Tn 5382 and Tn
1549. Hence, a positive vanB PCR is poorly predictive and
requires culture to diﬀerentiate VRE positive patients from
VRE negative patients (i.e., PCR false positive) and hence,
the vanB gene is the only one detected in our group of
patients. Relying on a positive vanB result in our hospital
would result in unnecessary utilization of hospital resources
and infection control prevention measures for patients who
arenotharboringVRE.Inthisstudy,theBDGeneOhmvanR
negative predictive value was 100%. We need to weigh the
convenience of rapid negative results with the requirement
for additional testing. In conclusion, the BD GeneOhm vanR
Assay may be used as a rapid screening method for vanA
and vanB carriers, given the high sensitivity and negative
predictive value. However, the high number of false positive
forvanBwillnecessitatecultureconﬁrmationoftheseresults.
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